Skip to content
Homepage
Author:
Cabaletta Bio
Posted Date:
June 3, 2026
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Cabaletta Bio
June 3, 2026
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio
May 14, 2026
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Cabaletta Bio
May 14, 2026
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
Cabaletta Bio
May 4, 2026
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Cabaletta Bio
April 28, 2026
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
Cabaletta Bio
April 27, 2026
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Cabaletta Bio
March 23, 2026
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
Cabaletta Bio
February 24, 2026
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Cabaletta Bio
February 7, 2026
